CALGB 89803 Trial

The CALGB 89803 trial investigated whether adding chemotherapy after surgery could improve survival for patients with colon cancer. Participants with stage III colon cancer were randomly assigned to receive either a standard chemotherapy regimen or no additional treatment. The study aimed to determine if chemotherapy reduced the risk of cancer recurrence and increased overall survival. Results showed that patients who received chemotherapy had a significantly lower risk of cancer returning and lived longer than those who did not receive extra treatment, helping establish chemotherapy as a standard part of treatment for stage III colon cancer.